Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Metastatic castration-resistant prostate cancer
0.010 Biomarker disease BEFREE <b>Purpose:</b> Sipuleucel-T is FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on the IMPACT trial showing a 4.1-month benefit in median overall survival (OS) for patients receiving sipuleucel-T versus control. 29858218 2018